NCT02354547 2025-05-30
A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors
SynerGene Therapeutics, Inc.
Phase 1 Suspended
SynerGene Therapeutics, Inc.
Anaeropharma Science, Inc.
Eisai Inc.
Synta Pharmaceuticals Corp.
Eisai Inc.
Adherex Technologies, Inc.
Exelixis